Adaptive dynamic artificial polyligand targeting (ADAPT): A Method to identify exosomal proteins from a prostate cancer cell line


Tassilo Hornung, Stephen C. Logie, Aniket S. Bondre, Varun Maher, Melissa N. Richards, Jelena Zarkovic, Teresa T. Tinder, Heather A. O’Neill, Mark R. Miglarese and David B. Spetzler


In the recent years it was demonstrated that a multitude of body fluids contain substantial amounts of exosomes, extracellular vesicles with sizes ranging between 40 and 100 nm. Those vesicles have protein profiles characteristic of their cells of origin. It was shown that exosomes play a role in cell-to-cell communication making them attractive targets to identify early disease stage biomarkers. Cancer heterogeneity has been known for a long time to be an important clinical determinant of patient outcome. We developed the highly multiplexed ADAPT platform to capture systems-based biological signatures that may reflect the molecular heterogeneity of various cancer types and help to improve diagnosis of the disease1. In order to show the potential of the ADAPT Biotargeting System™ on extracellular vesicles, exosomes from two prostate cancer cell lines, VCaP and LNCaP, were used to train ssDNA libraries to discriminate them


  • Successful selection of ODNs that bind preferably to exosomes from one cell line.
  • Identification and verification of proteins as binding partners for selected ODNs.

ADAPT is an unbiased profiling platform that identifies proteins expressed on exosomes. This platform can be deployed against multiple sample types and offers broad potential applications in biomarker discovery

Download Publication